Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
285 hedge funds and large institutions have $3.51B invested in Amedisys in 2019 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 105 increasing their positions, 105 reducing their positions, and 75 closing their positions.
2.44% more ownership
Funds ownership: 88.11% → 90.56% (+2.4%)
1% more capital invested
Capital invested by funds: $3.47B → $3.51B (+$44.8M)
0% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 105
10% less funds holding
Funds holding: 317 → 285 (-32)
35% less first-time investments, than exits
New positions opened: 49 | Existing positions closed: 75
48% less call options, than puts
Call options by funds: $15.7M | Put options by funds: $30.5M
Top Buyers
Top Sellers
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$88.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$33.3M |
| 3 |
Millennium Management
New York
|
-$26.7M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$25.9M |
| 5 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
-$23.2M |
AMED Hedge Fund Activity: Q2 2019 in Review
285 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q2 2019, worth a combined $3.51B — up 1.3% from $3.47B a quarter earlier.
Sellers outnumbered buyers: 75 funds closed out of AMED and 49 opened new positions — a net loss of 26 holders — while 105 trimmed existing stakes and 105 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $119M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $88.9M sold.
- 285 institutional investors held Amedisys (AMED) as of Q2 2019, down from 317 in Q1 2019.
- Funds reported $3.51B of Amedisys stock for Q2 2019, up 1.3% quarter-over-quarter.
- 49 funds opened new Amedisys positions in Q2 2019 and 75 closed out, a net change of -26 holders.
- The largest Amedisys buyer in Q2 2019 was T. Rowe Price Associates, an estimated $119M added.
- The largest Amedisys seller in Q2 2019 was Acadian Asset Management, an estimated $88.9M sold.
Based on aggregated 13F filings for Q2 2019.